Myoung Joo Kang
Cancer Center
Specialty
Solid tumor(Stomach cancer, Colon cancer, Pancreatic cancer, Hepatobiliary cance
Treatment hours
| Mon | Tue | Wed | Thu | Fri | Sat |
|---|
- 바로가기 메뉴
- 본문 바로가기
- 주메뉴 바로가기
Dec
-
- Date
- 2(Mon)
- 3(Tue)
- 1(Wed)
- 2(Thu)
- 3(Fri)
- 4(Fri)
-
- AM
-
- PM
-
- Date
- 6(Mon)
- 7(Tue)
- 8(Wed)
- 9(Thu)
- 10(Fri)
- 11(Fri)
-
- AM
-
Ambulatory
-
- PM
-
Ambulatory
-
- Date
- 13(Mon)
- 14(Tue)
- 15(Wed)
- 16(Thu)
- 17(Fri)
- 18(Sat)
-
- AM
-
Ambulatory
-
Ambulatory
-
- PM
-
Ambulatory
-
Ambulatory
-
- Date
- 20(Mon)
- 21(Tue)
- 22(Wed)
- 23(Thu)
- 24(Fri)
- 25(Sat)
-
- AM
-
Ambulatory
-
- PM
-
Ambulatory
-
- Date
- 27(Mon)
- 28(Tue)
- 29(Wed)
- 30(Thu)
- 31(Fri)
- 1(Sat)
-
- AM
-
Ambulatory
-
Ambulatory
-
- PM
-
Ambulatory
-
Ambulatory
- Education/Career/Main Activities
- Research/Publication
- Press Board
Education
1998. 3 ? 2002. 2 M.D.
College of Medicine
Inje University
Busan, Korea
2007. 3 ? 2009. 2 Master of Science
Postgraduate School
Inje University
Busan, Korea
2011.3- 2015.2 Ph.D.
Internal Medicine
College of Medicine
Graduate School of Kosin University
Busan, Korea
2017.4 - Associate professor
Department of Hemato-Oncology
Haeundae Paik Hospital
University of Inje College of Medicine
Busan, Korea
Career
1998. 3 ? 2002. 2 M.D.
College of Medicine
Inje University
Busan, Korea
2007. 3 ? 2009. 2 Master of Science
Postgraduate School
Inje University
Busan, Korea
2011.3- 2015.2 Ph.D.
Internal Medicine
College of Medicine
Graduate School of Kosin University
Busan, Korea
2017.4 - Associate professor
Department of Hemato-Oncology
Haeundae Paik Hospital
University of Inje College of Medicine
Busan, Korea
Main Activities
Clinicl study for solid tumor, palliative treatment, chemotherapy
Research/Publication
2006-2017 SCI, SCIE
1. Kang MJ, Ryoo BY, Ryu MH, Koo DH, Chang HM, Lee JL, Kim TW, Kang YK. Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience. Eur J Cancer. Mar;48(4):492-500, 2012.
2. Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs. Aug;30(4):1607-13, 2012
3. Kang MJ, Lee JL, Kim TW, Lee SS, Ahn S, Park DH, Lee SS, Seo DW, Lee SK, Kim MH. Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncol. Sep;51(7):860-6, 2012.